Thermo Fisher Scientific Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended December 31, 2021. The filing reports annual results; it does not provide a standalone fourth-quarter financial summary in the supplied text.
Business context
Thermo Fisher serves life sciences, pharmaceutical and biotech, healthcare and diagnostics, academic and government, and industrial markets. Its four reporting segments are Life Sciences Solutions, Analytical Instruments, Specialty Diagnostics, and Laboratory Products and Biopharma Services. PPD, a clinical research services provider, was acquired on December 8, 2021 and added to the Laboratory Products and Biopharma Services segment.
Financial results and liquidity
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $39.211 billion | $32.218 billion | +22% |
| Organic revenue growth | 17% | Non-GAAP | |
| GAAP operating income | $10.028 billion | $7.794 billion | +29% |
| GAAP operating margin | 25.6% | 24.2% | +1.4 percentage points |
| Adjusted operating income | $12.138 billion | $9.556 billion | +27% |
| Adjusted operating margin | 31.0% | 29.7% | +1.3 percentage points |
| Net income attributable to Thermo Fisher | $7.725 billion | $6.375 billion | +21% |
| GAAP diluted EPS | $19.46 | $15.96 | +22% |
| Adjusted EPS | $25.13 | $19.56 | +28% |
| Operating cash flow | $9.312 billion | $8.289 billion | +12% |
| Free cash flow | $6.809 billion | $6.823 billion | Nearly flat; non-GAAP |
- Cash and cash equivalents were $4.477 billion at year-end, versus $10.325 billion a year earlier. Total debt was $34.870 billion, up from $21.735 billion, primarily reflecting financing for PPD and other corporate purposes. Short-term obligations and current maturities were $2.537 billion.
- Net cash used in investing activities was $21.932 billion, including $19.395 billion for acquisitions and $2.523 billion of capital expenditures. The company reported $6.581 billion of net cash from financing activities.
- Net interest expense was $493 million, compared with $488 million. Cash taxes paid were $2.182 billion, versus $1.324 billion.
Changes versus FY2020
- Growth was broad-based, with reported revenue increases in all four segments. Segment revenue and operating-income trends included: Life Sciences Solutions, $15.631 billion and $7.817 billion; Analytical Instruments, $6.069 billion and $1.197 billion; Specialty Diagnostics, $5.659 billion and $1.280 billion; and Laboratory Products and Biopharma Services, $14.862 billion and $1.844 billion.
- Analytical Instruments’ segment margin rose to 19.7% from 15.8%, helped by higher sales and the absence of a $108 million long-term supply-contract charge recorded in 2020. Specialty Diagnostics’ margin declined to 22.6% from 25.6%, mainly due to sales mix and growth investments. Life Sciences Solutions’ margin was 50.0% versus 50.2%; Laboratory Products and Biopharma Services’ margin increased to 12.4% from 10.4%.
- COVID-19-related product sales were $9.23 billion, up from $6.63 billion. Currency translation added approximately $619 million to revenue; acquisitions contributed 3 percentage points and currency 2 percentage points to reported growth.
- GAAP other expense was $694 million, compared with $76 million, and included $767 million of losses on early debt extinguishment and $36 million of PPD-related bridge financing costs. These items contributed to the difference between GAAP and adjusted earnings.
Outlook, commentary and risks
- Management expected positive COVID-19-related revenue effects to continue into 2022, but said their duration and scale were uncertain and dependent largely on testing, therapy and vaccine demand. The filing provides no 2022 revenue or EPS guidance in the supplied text.
- For 2022, the company expected capital expenditures of $2.5–$2.7 billion, a GAAP effective tax rate of 9%–11%, and an adjusted tax rate of approximately 13%.
- Management attributed stronger margins primarily to profit on higher sales and sales mix, partly offset by strategic growth investments. It cited continued demand across end markets and ongoing investments in capacity and capabilities.
- Key risks include uncertainty in pandemic-related demand, supply-chain constraints and inflation, reliance on some sole- or limited-source suppliers, competition and technology shifts, regulatory and product-quality obligations, cybersecurity and privacy exposure, foreign-exchange risk, and integration of PPD. The company also noted that higher leverage could constrain financing flexibility; its revolving facility requires a minimum interest coverage ratio of 3.5:1.0.
- PPD’s acquisition was a major unusual transaction: net cash consideration was $15.99 billion, and acquired goodwill was $13.781 billion. The company reported $41.924 billion of goodwill and $18.878 billion of definite-lived intangible assets at year-end. Integration execution and the value of acquired intangibles are important areas of judgment.
- Environmental liabilities were accrued at $65 million. The estimated range of probable loss for continuing-operations product liability, workers’ compensation and other personal injury matters was approximately $216–$375 million undiscounted; the recorded accrual was $216 million. The company cautioned that an unfavorable outcome beyond accrual estimates could materially affect results, financial position or cash flows.
Important facts for investors to verify
- How much of FY2021 growth and profitability is sustainable without elevated COVID-19-related sales, and how demand evolves in 2022.
- PPD’s ongoing contribution, integration costs and synergies, alongside the acquisition-related debt and amortization burden.
- Debt repayment and liquidity plans, including the effect of commercial paper, upcoming maturities and capital allocation.
- Cash conversion and working-capital trends, especially the $1.065 billion cash use from higher inventories in 2021.
- Assumptions underlying non-GAAP adjusted earnings, organic growth and free cash flow, and the company’s reconciliation of these measures to GAAP.
- Potential changes in litigation, environmental, tax and other contingencies, and the excluded acquired businesses’ internal-control integration status.